Cell and Gene Therapy Catapult at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Cell and Gene Therapy Catapult brings 3 presentations to ESGCT 2026 in Hamburg. Its contributions centre on making viral and non-viral gene therapy manufacture cheaper and cleaner. One looks at cutting residual nucleic acid impurities in rAAV production by overexpressing a human nuclease, another at continuous rAAV manufacturing.
| Organization | ESGCT 2026 Attendance |
|---|---|
Cell and Gene Therapy Catapult London, UK | |
Independent innovation centre helping cell and gene therapy developers translate, scale and manufacture therapies, including a manufacturing centre in Stevenage. | Poster Thu Oct 29 2:00pm–4:00pm Advancing non-viral in vivo gene therapies from innovation to clinical readiness Poster Thu Oct 29 2:00pm–4:00pm Overcoming rAAV gene therapy cost barriers through intensified and continuous manufacturing Poster Thu Oct 29 2:00pm–4:00pm Reducing residual nucleic acid impurities in rAAV production through human nuclease overexpression |
Instantly find 20 buyers from Cell and Gene Therapy Catapult
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction